SCOTUS setback won’t end FTC’s focus on pharma patent strategies

In AMG Capital Management v FTC, the Supreme Court stripped the Federal Trade Commission of its ability to seek monetary relief for patent-related antitrust infractions.

Get unlimited access to all IAM content